Atlas Trials

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Clinical trial NCT05967689 · RECRUITING

Trial details

NCT number
NCT05967689
Sponsor
Taiho Oncology, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Start date
2023-07-31
Primary completion
2028-08-31
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.